Angiotensinogen Reconsidered: Evolving Perspectives in Hypertension Research - PubMed
3 hours ago
- #angiotensinogen
- #hypertension
- #RNA-therapeutics
- Hypertension is a major risk factor for cardiovascular diseases, stroke, and kidney disease.
- Angiotensinogen (AGT) was historically seen as a passive substrate but is now recognized as an active regulator of blood pressure.
- AGT responds to metabolic, hormonal, and inflammatory stimuli, playing a dynamic role in blood pressure regulation.
- Genetic variants like M235T and -6G>A influence susceptibility to hypertension.
- AGT is implicated in salt-sensitive hypertension, obesity-related inflammation, and RAAS escape phenomena.
- RNA-based therapies (e.g., zilebesiran, tonlamarsen) show promise in clinical trials for lowering blood pressure.
- AGT may serve as a biomarker for hypertensive nephropathy and treatment response.
- Targeting AGT offers new precision medicine approaches for conventional and resistant hypertension.